How many insider trades does FilingIQ track for MAZE?

FilingIQ tracks 133 Form 4 insider transactions for MAZE (Maze Therapeutics, Inc.), covering filings from Feb 3, 2025 onwards. 51 of those were filed in the last 90 days.

Are MAZE insiders net buyers or net sellers?

Across the full Form 4 history for MAZE, 0 transactions (0%) were open-market purchases and 44 (33%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does MAZE insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is MAZE in?

Maze Therapeutics, Inc. (MAZE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.42B.

MAZE insider trading

NasdaqGM Healthcare

Maze Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

133

Last 90 days

Buys / sells

0% / 33%

Market cap

$2.42B

About Maze Therapeutics, Inc.

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. The company also offers MZE001, a clinical program for the treatment of Pompe disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

Company website: www.mazetx.com

MAZE insider activity at a glance

FilingIQ has scored 133 insider transactions for MAZE since Feb 3, 2025. The most recent filing in our index is dated May 4, 2026.

Across the full history, 0 open-market purchases and 44 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on MAZE insider trades is 66.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live MAZE trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for MAZE?: FilingIQ tracks 133 Form 4 insider transactions for MAZE (Maze Therapeutics, Inc.), covering filings from Feb 3, 2025 onwards. 51 of those were filed in the last 90 days.
Are MAZE insiders net buyers or net sellers?: Across the full Form 4 history for MAZE, 0 transactions (0%) were open-market purchases and 44 (33%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does MAZE insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is MAZE in?: Maze Therapeutics, Inc. (MAZE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.42B.

Methodology & sources

Every MAZE insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.